Loading...

AXIM Biotechnologies, Inc.

AXIM•PNK
Healthcare
Biotechnology
$0.007
$0.001(16.28%)

AXIM Biotechnologies, Inc. (AXIM) Stock Overview

Explore AXIM Biotechnologies, Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B+

Score: 70.6/100

Key Financials

Market Cap2.1M
P/E Ratio-0.64
EPS (TTM)$-0.02
ROE0.38%
Fundamental Analysis

AI Price Forecasts

1 Week$0.01
1 Month$0.01
3 Months$0.04
1 Year Target$0.03

AXIM Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of AXIM Biotechnologies, Inc. (AXIM) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $0.03.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.64 and a market capitalization of 2.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
78.29%
↑ 78.29%
Profit Growth
$-0.01
↑ 56.42%
EPS Growth
$-0.01
↑ 68.93%
Operating Margin
-2506.28%
↑ 35.91%
ROE
37.56%
↑ 56.42%
Dividend Yield
0.00%
Analyst Recommendations data is not available for AXIMAnalyst Recommendations details for AXIM are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

AXIM Biotechnologies, Inc. develops and sells diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and oncology. The company is developing rapid diagnostic tests, which measure the levels of functional neutralizing antibodies that prevent SARS-CoV-2 from attaching to human cells; serological diagnostic test, which detect neutralizing antibodies that measure adaptive immune response to the SARS-CoV-2 virus; and tests for management of COVID-19 Patients to detect biomarkers related to inflammation. It is also developing rapid quantitative tear tests for Matrix metalloproteinase-9, an inflammatory biomarker for dry eye disease; SBI-183, an anti-metastatic compound suppressing tumor cell growth and blocking metastasis; and SPX-1009, an anti-metastatic treatment to measure levels of quiescin sulfhydryl oxidase I. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.

CEO

Catalina Valencia

Employees

6

Headquarters

6191 Cornerstone Court, East, San Diego, CA

Founded

2014

Frequently Asked Questions

;